Recent Molecular Targets and their Ligands for the Treatment of Alzheimer Disease

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by multiple pathologies including cholinergic dysfunction, amyloid-beta (Aβ) toxicity, tauopathies, oxidative stress, and neuroinflammation.
• Current therapeutic strategies often target single pathways, which may be insufficient for a multifaceted disease like AD.

Purpose of the Study:

• To review recent advancements in identifying novel druggable targets for Alzheimer's disease.
• To explore the potential of multi-target directed ligands (MTDLs) in addressing the complex pathologies of AD.
• To provide insights into ligands targeting pathways such as cannabinoid receptors, matrix metalloproteinases (MMPs), histone deacetylase (HDAC), and various kinases.

Main Methods:

• Literature review of recent biochemical and pharmacological studies on Alzheimer's disease.
• Identification and analysis of emerging druggable targets and their associated ligands.
• Focus on pathways implicated in AD pathogenesis, including neuroinflammation and protein aggregation.

Main Results:

• Several novel biochemical pathways have been identified as potential druggable targets for AD.
• Cannabinoid receptors, MMPs, HDACs, and kinases (GSK-3β, MAPK, JNK) are highlighted as promising targets.
• The development of MTDLs offers a promising strategy to simultaneously address multiple AD pathologies.

Conclusions:

• Multi-target directed ligands represent a promising therapeutic avenue for Alzheimer's disease.
• Targeting novel pathways beyond traditional approaches may lead to more effective treatments.
• Further research into these targets and ligands is crucial for developing realistic therapeutic insights.